Lifecore Biomedical, Inc. (LFCR)

Market Cap	191.67M
Revenue (ttm)	103.27M
Net Income (ttm)	-99.56M
Shares Out	30.86M
EPS (ttm)	-3.32
PE Ratio	n/a
Forward PE	10.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,963
Open	6.17
Previous Close	6.07
Day's Range	5.90 - 6.27
52-Week Range	4.47 - 11.46
Beta	0.97
Analysts	Buy
Price Target	9.50 (+52.98%)
Earnings Date	Aug 29, 2024

About LFCR

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Employees: 459
• Stock Exchange: NASDAQ
• Ticker Symbol: LFCR

Financial Performance

In 2023, LFCR's revenue was $103.27 million, a decrease of -7.19% compared to the previous year's $111.27 million. Losses were -$99.56 million, -14.70% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 52.98% from the latest price.

Price Target

$9.5

(52.98% upside)

Analyst Consensus: Buy